Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Featuring Tina Bhutani, MD, MAS | CEO, Synergy Dermatology Associate Clinical Professor of Dermatology University of California, SF San Francisco, CA | Published February 16, 2023